P
Pierre L. Beaulieu
Researcher at Boehringer Ingelheim
Publications - 135
Citations - 4781
Pierre L. Beaulieu is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: Hepatitis C virus & Polymerase. The author has an hindex of 36, co-authored 133 publications receiving 4640 citations.
Papers
More filters
Journal ArticleDOI
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
Daniel Lamarre,Paul C. Anderson,Murray D. Bailey,Pierre L. Beaulieu,Gordon Bolger,Pierre R. Bonneau,Michael Bös,Dale R. Cameron,Mireille Cartier,Michael G. Cordingley,Anne-Marie Faucher,Nathalie Goudreau,Stephen H. Kawai,George Kukolj,Lisette Lagacé,Steven R. LaPlante,Hans Narjes,Marc-André Poupart,Jean Rancourt,Roel E. Sentjens,Roger St. George,Bruno Simoneau,Gerhard G. Steinmann,Diane Thibeault,Youla S. Tsantrizos,Steven M. Weldon,Chan-Loi Yong,Montse Llinas-Brunet +27 more
TL;DR: Administration of BILN 2061 to patients infected with HCV genotype 1 for 2 days resulted in an impressive reduction of HCV RNA plasma levels, and established proof-of-concept in humans for an HCV NS3 protease inhibitor, illustrating the potential of the viral-enzyme-targeted drug discovery approach for the development of new HCV therapeutics.
Patent
Viral Polymerase Inhibitors
Youla S. Tsantrizos,Catherine Chabot,Pierre L. Beaulieu,Christian Brochu,Martin Poirier,Timothy A. Stammers,Bounkham Thavonekham,Rancourt Jean +7 more
TL;DR: An enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein A, B, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein, or a salt or ester thereof, as an inhibitor of HCV NS5B polymerase.
Journal ArticleDOI
A Practical Oxone®-Mediated, High-Throughput, Solution-Phase Synthesis of Benzimidazoles from 1,2-Phenylenediamines and Aldehydes and its Application to Preparative Scale Synthesis
TL;DR: In this article, a mixture of a 1,2-phenylenedi-amine and an aldehyde in wet DMF at room temperature is used to synthesize benzimidazoles.
Journal ArticleDOI
Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase.
George Kukolj,Graham A. McGibbon,Ginette McKercher,Martin Marquis,Sylvain Lefebvre,Louise Thauvette,Jean Gauthier,Sylvie Goulet,Marc-André Poupart,Pierre L. Beaulieu +9 more
TL;DR: A novel class of compounds and unique binding site expand the diversity of HCV antivirals currently under development and offer the potential to improve the treatment of chronic HCV infection.
Journal ArticleDOI
A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo
Michel Liuzzi,Robert Deziel,Nell Moss,Pierre L. Beaulieu,Anne-Marie Bonneau,Christiane Bousquet,James G. Chafouleas,Michel Garneau,Jorge Jaramillo,Richard Krogsrud,Lisette Lagacé,Robert S. McCollum,Sopone Nawoot,Yvan Guindon +13 more
TL;DR: BILD 1263 is reported on, which to the authors' knowledge is the first HSV RNR subunit-association inhibitor with antiviral activity in vivo and may lead to the design of new strategies to treat herpesvirus infections in humans.